Updated May 2022
Trial Short Name | Molecular Target(s) | Patient Population | Lead Investigator(s) in Cambridge |
ACTion | IL-23 / AR | mCRPC (pre chemotherapy, progression on Abiraterone/ Enzaltuamide/ similar) | S Pacey |
ATRiUM | ATR | Solid tumours- ATR with gemcitabine. Particular interest in ARID1A mut, ATM loss | D Jodrell |
AZD1390 | ATM with RT | Glioblastoma | S Jefferies |
AZD5305 (PETRA) |
PARP |
Advanced breast, prostate, ovarian cancers. With mutations in: BRCA1 / BRCA2 / PALB2 / RAD51. AZD5305 A PARP1-isoform selective 2nd-gen PARP inhibitor |
R Baird |
AZD6738 | ATR | Ovarian cancer expansion (Post PARPi, BRCAm, platinum sensitive) | D Jodrell, B Basu |
AZD9833 (SERENA-1) | ER | ER+ HER2- advanced breast cancer- oral SERD in combination with abemaciclib/ everolimus / capivasertib | R Baird |
Basket of Baskets |
Multiple:
|
Advanced solid tumours- tumour DNA sequencing then therapy matched to molecular profile for subsets of patients:
|
R Baird |
BEGONIA |
Multiple:
|
1st line metastatic triple-negative breast cancer: durvalumab plus:
|
R Baird |
BT1718 | MT1-MMP | NSCLC, solid tumours with high MT1-MMP expression | B Basu |
BT5528 | EphA2 | Ovarian, urothelial. Solid tumours (EphA2 expressing) | B Basu |
CONCORDE-B (NCT04550104): | ATM with RT | A study of a DNA damage response inhibitor (ATMi; AZD1390) in combination with conventional, radical radiotherapy in non-small cell lung cancer (stage IIb/III). | H Yang/D Jodrell |
CCS1477 | P300/CBP | mCRPC or solid tumours with actionable target related to p300/CBP inhibition e.g. ARID1A/p300/CBP mt; / c-MYC amplification or tumour with high likelihood e.g. small cell cancer | S Pacey |
DESTINY-Breast-07 (NCT04538742): | HER2 | HER2-targeting ADC (TDXd) in combination with other anti-cancer therapies - 1st line treatment of metastatic HER2+ Breast Cancer | R Baird |
MCLA- 158 | LGR5/EGFR | Squamous cell head and neck cancer | E Smyth/ D Jodrell |
Merck M1774 (NCT04170153) | ARID1A, ATRX, DAXX, ATM | Metastatic or advanced solid tumours, ATR inhibitor | B Basu |
Nurix 1607 (NCT05107674) | Immunomodulator | Advanced solid tumours without treatment options, CBL-B inhibitor | S Pacey |
Paradigm-2 | PARP | GBM | S Jefferies |
PATRIOT | ATR | Any tumour type – palliative radiotherapy combined with ATR inhibitor | R Baird |
Timepoint- MTLCEBPα | PD1 and CEBP | Solid tumours- Ovarian, pancreatic, colorectal, oesophago-gastric, met. prostate, GBM TNBC | B Basu |